For example, increased expression levels of ADGRG1, ADGRE5, and ADGRF5 has been detected in a variety of human cancers such as glioma (ADGRG1) (Shashidhar et al., 2005), gastric (Liu et al., 2005), pancreatic (He et al., 2015), esophageal (Aust et al., 2002), prostate (Ward et al., 2011), colorectal carcinomas (Steinert et al., 2002) (ADGRE5), and breast cancer (ADGRF5) (Tang et al., 2013). This evidence concerns the gene ADGRF5 and central nervous system cancer.